Benign and malignant forms of erythroderma: Cutaneous immunophenotypic characteristics

Flow cytometric detection of peripheral blood involvement by mycosis fungoides and Sézary syndrome using T-cell receptor Vβ chain antibodies and its application in blood staging

“…This indicates that some flow cytometric surface aberrations are not necessarily indicative of T-cell malignancies. These findings agree with earlier observations that loss or dim expression of CD7 and CD26 can be found in patients with benign inflammatory dermatoses 17,34,35 and other reactive conditions, 14 and aberrant dim CD3 can be observed non-neoplastic T cells. 29 Similarly, T-cell receptor gene rearrangements have been detected in samples of patients without clinical or histologic evidence of lymphoma or evidence of T-cell clonality shown by other methods.…”

Revisions to the staging and classification of mycosis fungoides and Sézary syndrome: a proposal of the International Society for Cutaneous Lymphomas (ISCL) and the cutaneous lymphoma task force of the European Organization of Research and Treatment of Cancer (EORTC)

“…[102][103][104][105][106][107][108] Deletion of one or more of these markers on the surface of CD4 ϩ cells is typical of Sézary cells, but the blood of many patients with benign inflammatory dermatoses may also show CD7 deletion. 107,109,110 Loss of CD26 may be a more specific phenotype for the neoplastic lymphocytes. 104,108 Identification of neoplastic cells by flow cytometry is complicated, however, by the fact that all neoplastic lymphocytes may not have the same phenotypic features and several clones may be present in a given patient with SS.…”

Sézary syndrome: Immunopathogenesis, literature review of therapeutic options, and recommendations for therapy by the United States Cutaneous Lymphoma Consortium (USCLC)

“…However, the blood of patients with benign inflammatory dermatoses may also show CD26 or CD7 deletion. 11,12,15 In addition, the correlation of the blood tumor burden by flow cytometry and by SC preparation is inexact and may offer differing results from center to center unless a single observer or a panel of experts is used to read the slides. Expansion of a clonal T-cell population assessed by polymerase chain reaction or Southern blotting to demonstrate a dominant T-cell receptor (TCR) gene rearrangement in the blood, although also not specific for lymphoma, [16][17][18] provides supportive evidence for significant blood involvement in the presence of an increased number of atypical lymphocytes or SCs by cytopathologic or immunophenotypic evaluation, especially if the clonal T-cell population is the same in skin and blood.…”